Peptide Companion
Back to catalog
Peptide Companion
single
Growth Hormone
Vial: 5 mg

Ipamorelin (5 mg Vial)

Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue by mimicking ghrelin at the GH secretagogue receptor. Its key advantage is high specificity for GH release without triggering ACTH or cortisol elevation, making it one of the safer GH secretagogues with minimal off-target hormonal effects. This educational protocol presents a once-daily subcutaneous approach using practical dilution for precise insulin-syringe measurements.

Dose
0.2–0.3 mg per injection
Frequency
2–3 times daily
Timing
Morning, post-workout, before bed
Duration
8–12 weeks

Selective GH secretagogue. Minimal cortisol/prolactin elevation. Excellent safety profile.

Dosing Schedule
WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–2100 mcg6 units (0.06 mL)
Weeks 3–4150 mcg9 units (0.09 mL)
Weeks 5–8200 mcg12 units (0.12 mL)
Weeks 9–12250 mcg15 units (0.15 mL)
Supplies Needed
  • •Peptide Vials (Ipamorelin, 5 mg each):
  • •Insulin Syringes (U-100):
  • •Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
References

  • Translational Andrology and Urology (PMC)

    Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males (2020 review)

    View source

  • European Journal of Endocrinology (PubMed)

    Ipamorelin, the first selective growth hormone secretagogue (1998 preclinical pharmacology study)

    View source

  • European Journal of Anatomy

    Chronic in vivo Ipamorelin treatment stimulates body weight gain and growth hormone (GH) release in vitro in young female rats (2002 animal study on chronic dosing)

    View source

  • Pharmaceutical Research (PubMed)

    Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (1999 Phase I clinical pharmacology study)

    View source

  • European Journal of Anatomy

    Three-week chronic in vivo ipamorelin treatment: no desensitization of GH release mechanisms (2002 animal study)

    View source

  • International Journal of Colorectal Disease (PubMed)

    Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (2014 Phase II clinical trial)

    View source

  • Johns Hopkins Arthritis Center

    How to Give a Subcutaneous Injection (patient educational resource)

    View source

  • NCBI Bookshelf

    Best practices for injection: asepsis, preparation, and administration techniques

    View source

  • Pharmacologic Considerations (PMC)

    Subcutaneous drug injection: review of pharmacologic considerations and site rotation practices

    View source

  • NIBSC (National Institute for Biological Standards)

    Peptide Handling, Dissolution & Storage Guidelines (peptide storage recommendations)

    View source

  • Bachem (Peptide Manufacturer)

    Handling and Storage Guidelines for Peptides (technical best-practices)

    View source

  • Creative Peptides

    How Long Do Peptides Last? Peptide Stability & Shelf Life (technical article on peptide stability)

    View source

Educational content adapted from peptidedosages.com. Not medical advice.